CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-06 | Aziz Kabeer Director | Other acquisition | +26,511 | $15.00 | $398K | 413,156 |
| 2022-06-06 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Other disposition | −26,511 | $15.00 | $398K | 2,184,224 |
| 2022-06-06 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Other acquisition | +26,511 | $15.00 | $398K | 413,156 |
| 2022-05-12 | Chanda Sanjay Chief Development Officer | Grant or award · Stock Option (right to buy) | +66,000 | 66,000 | ||
| 2022-05-12 | Readnour Robin Shane Director | Grant or award · Stock Option (right to buy) | +20,724 | 20,724 | ||
| 2022-05-12 | Eckburg Paul Chief Medical Officer | Grant or award · Stock Option (right to buy) | +66,000 | 66,000 | ||
| 2022-05-12 | Martin Patricia A. Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Wong Stephanie Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Nazak Michael Adrian Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +14,300 | 14,300 | ||
| 2022-05-12 | FitzPatrick Margaret M Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Aziz Kabeer Director | Grant or award · Stock Option (right to buy) | +20,724 | 20,724 | ||
| 2022-05-12 | Spigelman Melvin K Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Krause Kevin Michael Chief Strategy Officer | Grant or award · Stock Option (right to buy) | +66,000 | 66,000 | ||
| 2022-05-12 | Day Lucy Chief Financial Officer | Grant or award · Stock Option (right to buy) | +66,000 | 66,000 | ||
| 2022-05-12 | Zakrzewski Joseph S Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Marks Gilbert Lynn Director | Grant or award · Stock Option (right to buy) | +10,362 | 10,362 | ||
| 2022-05-12 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2022-05-05 | FitzPatrick Margaret M Director | Grant or award · Stock Option (right to buy) | +11,463 | 11,463 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +1,651,636 | 1,651,636 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +312,415 | 312,415 |
Page 17 of 20 · 385 trades